New Enterprise Associates , a tech start-up set up by T. Rowe Price founder Baillie Gifford , has announced that is has raised $ 110 m for its personalised cancer treatments. Founded in 2015 , the investment brings the company's total funding to $320m , along with a valuation of $ 2bn . Tempus said in a press release that the new funding would be used to expand its technology into new treatment areas beyond cancer, as well as to grow geographically. The funding came from new investors, including Eric Lefkofsky , Tempus , Revolution Growth and New Enterprise Associates , as well as existing stakeholders. In a press release, Tempus said the new funding would be used to expand its technology into new treatment areas, beyond cancer, as well as to grow geographically.
New Enterprise Associates , a tech start-up set up by T. Rowe Price founder Baillie Gifford , has announced that is has raised $ 110 m for its personalised cancer treatments. Founded in 2015 , the investment brings the company's total funding to $320m , along with a valuation of $ 2bn . The funding came from new investors, including Eric Lefkofsky , Tempus , Revolution Growth and New Enterprise Associates , as well as existing stakeholders. In a press release, Tempus said the new funding would be used to expand its technology into new treatment areas, beyond cancer, as well as to grow geographically.